AMPH (Amphastar Pharmaceuticals) Tariff Resilience Score: 7/10 (As of Jun. 28, 2026)


AMPH Amphastar Pharmaceuticals Inc AMPH
83 GF Score
Price $21.78
GF Value $48.79
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Amphastar Pharmaceuticals Tariff Resilience Score?

Amphastar Pharmaceuticals AMPH +3.52% 83 Tariff Resilience Score is 7 as of Jun. 28, 2026. GuruFocus rates AMPH with a GF Score™ of 83/100 and a GF Value™ of $48.79 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 1,028 Drug Manufacturers companies, Amphastar Pharmaceuticals ranks better than 97.08% on this metric.

Amphastar Pharmaceuticals has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Amphastar Pharmaceuticals has Amphastar Pharmaceuticals has a global supply chain but benefits from industry-specific exemptions. The company has moderate pricing power and can mitigate some tariff impacts through alternative sourcing. Historical impacts have been limited, supporting resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Amphastar Pharmaceuticals might have Highly Resilient.

Amphastar Pharmaceuticals  (NAS:AMPH) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Amphastar Pharmaceuticals Tariff Resilience Score Related Terms

AMPH vs ETON, ESPR, BIOA: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amphastar Pharmaceuticals Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Amphastar Pharmaceuticals's Tariff Resilience Score falls into.


AMPH
83GF Score
Amphastar Pharmaceuticals Inc AMPH
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Amphastar Pharmaceuticals (AMPH) has a Tariff Resilience Score of 7 as of Jun. 28, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Amphastar Pharmaceuticals ranks #30 out of 1028 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Amphastar Pharmaceuticals' Tariff Resilience Score too high?
Amphastar Pharmaceuticals' current Tariff Resilience Score is 7. Based on the distribution chart, Amphastar Pharmaceuticals ranks #30 out of 1028 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amphastar Pharmaceuticals has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Tariff Resilience Score compare to ETON and ESPR?
According to the Drug Manufacturers industry distribution chart, Amphastar Pharmaceuticals ranks #30 out of 1028 companies for Tariff Resilience Score. This places Amphastar Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Amphastar Pharmaceuticals's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.79, compared to a current price of $21.78 — trading 55.4% below its estimated fair value. The current Tariff Resilience Score is 7. Amphastar Pharmaceuticals' overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current Tariff Resilience Score is 7 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?

Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued. The current stock price of $21.78 is trading 55.4% below its estimated GF Value™ of $48.79. GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for AMPH:

  • Tariff Resilience Score: 7
  • GF Value™: $48.79 vs. price of $21.78 (55.4% below fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amphastar Pharmaceuticals Business Description

Other Exchanges 29A:Germany
Address 11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
83GF Score

Get the complete analysis for AMPH

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.78
Price
$48.79
GF Value